Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects
Halberd (OTC: HALB) reports significant progress in its partnership with Athena GTX, which recently secured a $2,866,000 final development contract for their Smart Autonomous Critical Care System (S-ACCS). The collaboration focuses on two key technologies for Traumatic Brain Injuries (TBI) and Suicide Ideation treatment.
The partnership has led to two distinct development tracks: Athena's WatchDawg® Pilot Study leading the Suicide Ideation treatment project, and Halberd's TBI mitigation nasal spray development program at Mississippi State University. The company is pursuing FDA clearance for their LDX treatment program through Athena Telemedicine Partnership, (ATP), which combines pharmacy, nutraceuticals, monitoring, and psychological therapies for veteran mental health issues.
Halberd is currently seeking funding for FDA clinical trials, including a 30-50 participant Phase 1 and a 100-150 participant Phase 2 study. The company is also exploring opportunities with indigenous American tribes and pursuing additional government contracts, with two awards pending for the WatchDawg software portal and the Nasal Spray program.
Halberd (OTC: HALB) riporta progressi significativi nella sua partnership con Athena GTX, che ha recentemente ottenuto un contratto finale di sviluppo di $2.866.000 per il loro Sistema di Cura Critica Autonomo Intelligente (S-ACCS). La collaborazione si concentra su due tecnologie chiave per il trattamento delle Lesioni Cerebrali Traumatiche (TBI) e dell'ideazione suicidaria.
La partnership ha portato a due percorsi di sviluppo distinti: lo studio pilota WatchDawg® di Athena che guida il progetto di trattamento dell'ideazione suicidaria, e il programma di sviluppo di uno spray nasale per la mitigazione delle TBI di Halberd presso la Mississippi State University. L'azienda sta perseguendo l'approvazione della FDA per il loro programma di trattamento LDX attraverso la Partnership di Telemedicina Athena (ATP), che combina farmacia, nutraceutici, monitoraggio e terapie psicologiche per i problemi di salute mentale dei veterani.
Halberd sta attualmente cercando finanziamenti per studi clinici FDA, inclusi uno studio di Fase 1 con 30-50 partecipanti e uno studio di Fase 2 con 100-150 partecipanti. L'azienda sta anche esplorando opportunità con tribù americane indigene e perseguendo ulteriori contratti governativi, con due premi in attesa per il portale software WatchDawg e il programma di spray nasale.
Halberd (OTC: HALB) informa sobre avances significativos en su asociación con Athena GTX, que recientemente aseguró un contrato final de desarrollo por $2,866,000 para su Sistema de Cuidado Crítico Autónomo Inteligente (S-ACCS). La colaboración se centra en dos tecnologías clave para el tratamiento de Lesiones Cerebrales Traumáticas (TBI) y la ideación suicida.
La asociación ha llevado a dos vías de desarrollo distintas: el estudio piloto WatchDawg® de Athena que lidera el proyecto de tratamiento de la ideación suicida, y el programa de desarrollo de un spray nasal para la mitigación de TBI de Halberd en la Universidad Estatal de Mississippi. La empresa está buscando la aprobación de la FDA para su programa de tratamiento LDX a través de la Asociación de Telemedicina Athena (ATP), que combina farmacia, nutracéuticos, monitoreo y terapias psicológicas para problemas de salud mental de veteranos.
Halberd actualmente busca financiamiento para ensayos clínicos de la FDA, incluyendo un estudio de Fase 1 con 30-50 participantes y un estudio de Fase 2 con 100-150 participantes. La empresa también está explorando oportunidades con tribus indígenas americanas y buscando contratos gubernamentales adicionales, con dos premios pendientes para el portal de software WatchDawg y el programa de spray nasal.
Halberd (OTC: HALB)는 최근 Athena GTX와의 파트너십에서 중요한 진전을 보고했습니다. Athena GTX는 스마트 자율 중환자 치료 시스템(S-ACCS)을 위한 최종 개발 계약을 2,866,000달러에 확보했습니다. 이 협력은 외상성 뇌 손상(TBI) 및 자살 사고 치료를 위한 두 가지 핵심 기술에 중점을 두고 있습니다.
이 파트너십은 두 가지 독립적인 개발 경로로 이어졌습니다: Athena의 WatchDawg® 파일럿 연구가 자살 사고 치료 프로젝트를 이끌고 있으며, Halberd는 미시시피 주립대학교에서 TBI 완화를 위한 비강 스프레이 개발 프로그램을 진행하고 있습니다. 이 회사는 약국, 건강 보조 식품, 모니터링 및 심리 치료를 결합한 Athena 원격의료 파트너십(ATP)을 통해 LDX 치료 프로그램에 대한 FDA 승인을 추구하고 있습니다.
Halberd는 현재 30-50명의 참가자를 포함한 1상 및 100-150명의 참가자를 포함한 2상 연구를 위한 FDA 임상 시험 자금을 찾고 있습니다. 이 회사는 또한 미국 원주민 부족과의 기회를 탐색하고 있으며, WatchDawg 소프트웨어 포털과 비강 스프레이 프로그램을 위한 두 개의 정부 계약을 추구하고 있습니다.
Halberd (OTC: HALB) fait état de progrès significatifs dans son partenariat avec Athena GTX, qui a récemment obtenu un contrat de développement final de 2 866 000 $ pour son Système de Soins Critiques Autonomes Intelligents (S-ACCS). La collaboration se concentre sur deux technologies clés pour le traitement des lésions cérébrales traumatiques (TBI) et de l'idéation suicidaire.
Le partenariat a conduit à deux voies de développement distinctes : l'étude pilote WatchDawg® d'Athena qui dirige le projet de traitement de l'idéation suicidaire, et le programme de développement d'un spray nasal pour la mitigation des TBI de Halberd à l'Université d'État du Mississippi. L'entreprise recherche une autorisation de la FDA pour son programme de traitement LDX à travers le Partenariat de Télémédecine Athena (ATP), qui combine pharmacie, nutraceutiques, surveillance et thérapies psychologiques pour les problèmes de santé mentale des anciens combattants.
Halberd recherche actuellement des financements pour des essais cliniques auprès de la FDA, y compris une étude de Phase 1 avec 30 à 50 participants et une étude de Phase 2 avec 100 à 150 participants. L'entreprise explore également des opportunités avec des tribus amérindiennes et poursuit d'autres contrats gouvernementaux, avec deux prix en attente pour le portail logiciel WatchDawg et le programme de spray nasal.
Halberd (OTC: HALB) berichtet über bedeutende Fortschritte in seiner Partnerschaft mit Athena GTX, die kürzlich einen endgültigen Entwicklungsvertrag über 2.866.000 $ für ihr Smart Autonomous Critical Care System (S-ACCS) gesichert hat. Die Zusammenarbeit konzentriert sich auf zwei Schlüsseltechnologien für die Behandlung von traumatischen Hirnverletzungen (TBI) und Suizidgedanken.
Die Partnerschaft hat zu zwei unterschiedlichen Entwicklungswegen geführt: Die Pilotstudie WatchDawg® von Athena leitet das Projekt zur Behandlung von Suizidgedanken, während Halberd ein Nasenspray-Entwicklungsprogramm zur Minderung von TBI an der Mississippi State University verfolgt. Das Unternehmen strebt die Zulassung der FDA für sein LDX-Behandlungsprogramm über die Athena Telemedicine Partnership (ATP) an, die Apotheke, Nutraceuticals, Monitoring und psychologische Therapien für psychische Gesundheitsprobleme von Veteranen kombiniert.
Halberd sucht derzeit nach Finanzierungsmöglichkeiten für klinische Studien der FDA, einschließlich einer Phase-1-Studie mit 30-50 Teilnehmern und einer Phase-2-Studie mit 100-150 Teilnehmern. Das Unternehmen erkundet auch Möglichkeiten mit indigenen amerikanischen Stämmen und verfolgt weitere Regierungsverträge, wobei zwei Auszeichnungen für das WatchDawg-Softwareportal und das Nasenspray-Programm ausstehen.
- Secured $2.866M government contract for S-ACCS development
- Two additional government contract awards pending
- Successfully completed initial animal tests at Mississippi State University
- Filed provisional patent application based on pilot study results
- Expanded market potential identified for commercial applications
- Facing government funding delays
- Seeking alternative private funding sources
- Longer development timeline expected for TBI nasal spray product
- FDA clearance still pending for key products
The US Government Granted Athena GTX a
JACKSON CENTER, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) partnered with Athena GTX on a profit-sharing agreement over a year ago. This enabled Halberd to utilize Athena’s expertise and experience in dealing with the federal government. Of the two technologies associated with Traumatic Brain Injuries (TBI)/Suicide Ideation for which we chose to pursue government funding, Athena’s success via the WatchDawg® Pilot Study was chosen to lead the Suicide Ideation treatment project, while Halberd, via the successful Mississippi State University initial animal tests, leads the TBI mitigation nasal spray development program.
The website we established to do the hard work on market development and FDA clearance for our LDX adjunct treatment program is indeed now part of the Athena Telemedicine Partnership, LLC (ATP). That partnership involves the pharmacy, nutraceuticals, yoga/meditation, unique, wearable monitoring, and psychological therapists combining to service veteran mental health issues and suicidal ideation. This approach is significantly better, has been thoroughly documented as to clinical efficacy, and has permitted the filing of a provisional patent application based on the previous pilot study results.
Finally, we are currently seeking near-term funding to execute the FDA clearance plan for LDX, including both a 30-50 participant Phase 1 clinical trial and then a 100-150 participant Phase 2 study. We are also awaiting key demographic studies with the indigenous American tribes both here in the continental USA and in Alaska. The rates of mental health issues, alcoholism, and suicidal ideation are very large in these demographic areas.
These all are focused on obtaining the required safety and efficacy data for we need to get an FDA clearance via an expedited program this year. In light of government funding delays, we are negotiating with the private funding sector to support our ongoing work.
Our plan for commercialization of our LDN+/LDX PTSD/Suicidal ideation treatment product is to move to compounded pharmacy formulations under the appropriate compounding laws, until FDA clearance for the proprietary LDN+/LDX combined drug is achieved. After finishing a comprehensive government and commercial market assessment, we discovered that the projections for potential commercial applications are significantly higher than originally thought.
Concurrently, Halberd continues to lead the work with Mississippi State University on the TBI therapeutic nasal spray. In addition to pursuing government contracts, we have begun planning for Phase #2 animal studies. This nasal spray technology product is believed to require a longer-term development process, but we believe this product could offer an even greater market potential. We have pending government contract awards in this technology product and have completed critical proposals to support this work. We hope to hear positive response to our petitions shortly.
On the positive side, the Athena GTX team was awarded a
To get the latest on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/).
| For more information please contact: | |
| William A. Hartman | Mark Darrah, PhD |
| Chairman, CEO, President, Halberd Corp. | CEO Athena GTX |
| w.hartman@halberdcorporation.com | mmdarrah@athenagtx.com |
| support@halberdcorporation.com | www.athenagtx.com/ |
| www.halberdcorporation.com | |
| Twitter:@HalberdC | |
About Athena GTX, Inc.
Athena GTX is a certified DoD small business with Corporate Headquarters in Johnston, Iowa. Athena focuses development on wearables and highly mobile, wirelessly connected monitoring technologies, and transitioning those to key markets to meet unmet needs of first responders worldwide. Wireless Patient Monitoring – Athena GTX connects patient and provider About - Athena GTX® Inc.
About Halberd Corporation.
Halberd Corporation (OTC PINK: HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners. Halberd’s policy for responding to individual shareholder questions is to be responsive, while refraining from providing information which relates to or could compromise any information pertaining to trade secrets or that may otherwise compromise our competitive advantages. Simultaneously with such disclosure or potential disclosure, Halberd will make the responsive information public through a tweet, press release or some other form of social media/mass media communication.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company’ cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
(C) 2025, Halberd Corporation
FAQ
What is the value of the contract awarded to Athena GTX for the S-ACCS development?
How many participants are planned for HALB's LDX clinical trials?
What are the two main technology tracks in HALB's partnership with Athena GTX?
What services does HALB's Athena Telemedicine Partnership (ATP) combine?
